Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients.
2020
Summary
A retrospective chart review was conducted on 85 renal transplant patients aged 19–88 years, treated with denosumab or bisphosphonate therapy. Bone densitometry measures were compared between treatment groups at baseline; at years 1, 2, and 3; and at final follow-up (average of 3.4 years).
Both bisphosphonate and denosumab treatments increased lumbar spine bone density; however, the effect of denosumab was greater compared with that of bisphosphonate treatment. Denosumab treatment increased femoral neck BMD, whereas bisphosphonate treatment had a mean decrease in femoral neck BMD at final follow-up. Thus, our study provides evidence for the efficacy of denosumab treatment in renal transplant patients. Caution around hypocalcemia is warranted. We recommend more prospective studies to analyze the effects of long-term antiresorptive therapy in patients with a renal transplant.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
45
References
3
Citations
NaN
KQI